BBV-152 ANTIGEN ADJUVATED WITH ALGEL-IMDG

Summary

Bbv-152 Antigen Adjuvated With Algel-Imdg (CHEMBL4802199) is a phase-3 clinical-stage unknown; indicated across 1 condition including severe acute respiratory syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4802199
Name	BBV-152 ANTIGEN ADJUVATED WITH ALGEL-IMDG
Type	Unknown
Max phase	3

Also known as: Covaxin

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	1
PHASE2/PHASE3	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05142319	PHASE4	COMPLETED	Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]
NCT04918797	PHASE2/PHASE3	COMPLETED	COVAXIN in a Pediatric Cohort
NCT05522335	PHASE3	UNKNOWN	Phase III Study of BBV154 Intranasal Vaccine in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).